Table 1 Baseline characteristics for males and females of the low dose group (IGF-1 target level between − 2 and − 1 SDS) and the high dose group (IGF-1 target level between 1 and 2 SDS)
| Â | Males | Females | ||
|---|---|---|---|---|
Low Dose n = 10 | High Dose n = 11 | Low Dose n = 6 | High Dose n = 5 | |
Age (years) | 46.3 (11.2) | 47.4 (8.9) | 49.1 (10.7) | 44.3 (10.9) |
CO GH deficiency (%) | 80 | 27* | 33 | 0 |
Duration GH treatment (years) | 18.6 (9.4) | 13.4 (6.3) | 8.9 (5.3) | 4.8 (1.8) |
IGF-1 in SDS | 0.29 (0.62) | −0.38 (0.38)** | −0.08 (0.57) | − 0.03 (0.42) |
BMI (kg/m2) | 25.6 (3.4) | 28.6 (3.8) | 33 (14.5) | 29 (5.2) |
Cranial radiotherapy (%) | 10 | 18 | 0 | 0 |
Pituitary surgery (%) | 10 | 54 | 17 | 40 |
Isolated GH deficiency (%) | 20 | 26 | 33 | 0 |
LH/FSH deficiency (%) | 80 | 45 | 33 | 40 |
TSH deficiency (%) | 70 | 64 | 17 | 80 |
ACTH deficiency (%) | 80 | 64 | 33 | 60 |
ADH deficiency (%) | 0 | 36 | 0 | 0 |
Diabetes mellitus (%) | 10 | 0 | 33 | 0 |
CVD (%) | 0 | 18 | 50 | 40 |
Married (%) | 60 | 73 | 83 | 60 |
Education 10–13 years (%) | 30 | 18 | 16 | 40 |
Education > 13 years (%) | 70 | 82 | 83 | 60 |